| 1.4144 -0.046 (-3.12%) | 10-24 15:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.98 | 1-year : | 2.3 |
| Resists | First : | 1.69 | Second : | 1.97 |
| Pivot price | 1.5  |
|||
| Supports | First : | 1.26 | Second : | 1.04 |
| MAs | MA(5) : | 1.38  |
MA(20) : | 1.54 |
| MA(100) : | 1.64 |
MA(250) : | 1.84 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 21.6 |
D(3) : | 17.5 |
| RSI | RSI(14): 43.9 |
|||
| 52-week | High : | 3.48 | Low : | 1.26 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MAIA ] has closed above bottom band by 37.4%. Bollinger Bands are 129.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.54 - 1.55 | 1.55 - 1.56 |
| Low: | 1.38 - 1.39 | 1.39 - 1.4 |
| Close: | 1.45 - 1.46 | 1.46 - 1.47 |
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.
Fri, 24 Oct 2025
How high can MAIA Biotechnology Inc. stock go - Chart Signals & Risk Managed Investment Signals - newser.com
Fri, 24 Oct 2025
Predicting MAIA Biotechnology Inc. trend using moving averages - July 2025 Decliners & Reliable Volume Spike Trade Alerts - newser.com
Fri, 24 Oct 2025
Applying sector rotation models to MAIA Biotechnology Inc. - 2025 Market Sentiment & Free High Accuracy Swing Entry Alerts - newser.com
Thu, 23 Oct 2025
MAIA Biotechnology Showcases Promising Cancer Trial Results - TipRanks
Thu, 23 Oct 2025
MAIA Biotechnology Details 30-Month Patient Survival in Phase 2 NSCLC Trial - TradingView
Thu, 23 Oct 2025
MAIA Biotechnology (NYSE American: MAIA) details 30-month survival in THIO-101 NSCLC - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 24 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 16.3 (%) |
| Held by Institutions | 7.4 (%) |
| Shares Short | 633 (K) |
| Shares Short P.Month | 777 (K) |
| EPS | -1.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.12 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -107.2 % |
| Return on Equity (ttm) | -559.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.88 |
| PEG Ratio | 0 |
| Price to Book value | 10.92 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|